Drug Trial Radar · NCT02627274
A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Last checked: Nov 19, 2026Latest source record: Nov 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
134
Actual
Start
Dec 7, 2015
Primary completion
Nov 10, 2022
Study completion Nov 10, 2022
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 10, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human, open-label, multicenter, Phase Ia/Ib, adaptive, multiple ascending-dose study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of RO6874281 as a single agent (Part A) or in combination with trastuzumab or cetuximab (Part B or C).
Conditions
- Solid Tumor
- Breast Cancer
- Cancer of Head and Neck
Interventions
RO6874281Drug
RO6874281 will be administered as per the schedule specified under arm description.
TrastuzumabDrug
Trastuzumab will be administered as per the schedule specified under arm description.
CetuximabDrug
Cetuximab will be administered as per the schedule specified under arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Dose-Limiting Toxicities (DLTs)Time frame: Day 1 up to Day 21
- Maximum Tolerated Dose (MTD) of RO6874281Time frame: Day 1 up to Day 21
- Optimal Biological Dose (OBD) of RO6874281Time frame: Day 1 up to Day 21
- Recommended Dose for Further Development of RO6874281Time frame: Day 1 up to Day 21
- Systemic Clearance (CL) of RO6874281Time frame: Day 1 up to 24 months
- Volume of Distribution at Steady State (Vss) of RO6874281Time frame: Day 1 up to 24 months
- Area Under the Concentration-Time Curve (AUC) of RO6874281Time frame: Day 1 up to 24 months
- Maximum Observed Serum Concentration (Cmax) of RO6874281Time frame: Day 1 up to 24 months
Locations
26 sites in 9 countries. Site status is shown where the registry gives one.
University of Arizona Cancer Center
Tucson, Arizona
UCSD - Moores Cancer Center
La Jolla, California
Banner MD Anderson Cancer Center
Greeley, Colorado
Washington University; Division of Oncology
St Louis, Missouri
The Ohio State University
Columbus, Ohio
UZ Antwerpen
Edegem, Belgium
Juravinski Cancer Clinic; Department of Oncology
Hamilton, Ontario, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Rigshospitalet; Onkologisk Klinik
København Ø, Denmark
Institut Bergonie; Oncologie
Bordeaux, France
Centre Georges Francois Leclerc
Dijon, France
Centre Leon Berard
Lyon, France
Institut Claudius Regaud; Departement Oncologie Medicale
Toulouse, France
Institut Gustave Roussy; Sitep
Villejuif, France
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
Meldola, Emilia-Romagna, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori;S.S. Trattamento MedicoTumori dellaTesta e delCollo
Milan, Lombardy, Italy
Istituto Europeo di Oncologia; Svil. Nuovi Farmaci per Terapie Innovative
Milan, Lombardy, Italy
Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck
Milan, Lombardy, Italy
Ospedale Policlinico S. Matteo; Phase I Clinical Trial Unit and Experimental Therapy
Pavia, Lombardy, Italy
Antoni Van Leeuwenhoek Ziekenhuis; Gastro-Enterologie
Amsterdam, Netherlands
Erasmus MC
Rotterdam, Netherlands
Hospital Univ Vall d'Hebron; Servicio de Oncologia
Barcelona, Spain
Clinica Universitaria de Navarra
Pamplona, Navarre, Spain
Leicester Royal Infirmary
Leicester, United Kingdom
Guys and St Thomas NHS Foundation Trust, Guys Hospital
London, United Kingdom
Christie Hospital
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.